Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16171132 | 0.89 | GRK6 (0.49) | GRK6MAPTCHEK2SCN10ATP53 | |
| SCHEMBL21763932 | 0.83 | TDP1 (0.46) | GRK6MAPTTP53POLB | |
| SCHEMBL6411081 | 0.82 | SCN9A (0.47) | GRK6CHEK2POLBAURKATPX2 | |
| SCHEMBL14907754 | 0.80 | GRK6 (0.56) | GRK6KDM4E | |
| SCHEMBL11887741 | 0.79 | TYMP (0.57) | GRK6MAPTKDM4E | |
| SCHEMBL19425608 | 0.79 | TYMP (0.57) | GRK6MAPTSTK17BTP53POLB | |
| SCHEMBL6404365 | 0.79 | GRK6 (0.40) | GRK6CHEK2SCN10ASCN9A | |
| SCHEMBL14907798 | 0.79 | GRK6 (0.61) | GRK6MAPTKDM4E | |
| SCHEMBL6411809 | 0.78 | GRK6 (0.40) | GRK6SCN10ASCN9A | |
| SCHEMBL17214822 | 0.78 | STK17B (0.47) | GRK6MAPTSTK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-04-09 | — | — | US | disclosed |
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2014-10-16 | — | — | US | disclosed |
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2014-10-16 | — | — | US | disclosed |
| WO-2013063458-A2 | INHIBITING G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | GRK6 3937/4885MAPT 2111/4885CHEK2 1298/4885 |
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | GRK6, GRK2, GRK3 | GRK6 1/4885MAPT 4210/4885CHEK2 565/4885 |
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | GRK6, GRK2, GRK3 | GRK6 1/4885MAPT 4210/4885CHEK2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.